Drug transporters. Volume 2, Recent advances and emerging technologies /
This book comprehensively reviews current knowledge and techniques in the transporter sciences and their relations to drug metabolism and pharmacokinetics.
| Other Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Cambridge] :
Royal Society of Chemistry,
2016.
|
| Series: | RSC drug discovery series ;
55. |
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Cover; Contents; Preface; Acknowledgements; Abbreviations; Chapter 1 Emerging Transporter Science and Challenges for the Future; 1.1 Introduction; 1.2 Membrane Transporters of Emerging Importance; 1.3 Membrane Transporters in Less-studied Organs and Tissues; 1.3.1 Placenta; 1.3.2 Retina; 1.3.3 Heart; 1.3.4 Skin; 1.4 Organotypic In vitro Technologies; 1.4.1 Microfluidics; 1.4.2 3D Microplatforms; 1.4.3 3D Bioprinting; 1.5 Summary; References; Chapter 2 Enabling Dynamic Response to Chemical Challenge: Nuclear Receptor-mediated Control of Transporter Expression; 2.1 General Introduction
- 2.2 Nuclear Receptor Overview2.2.1 General Introduction; 2.2.2 Structure of Nuclear Receptors; 2.3 Localisation and Function of Nuclear Receptors; 2.3.1 Trans-activation; 2.3.2 Trans-repression; 2.4 Nuclear Receptors as Chemical Sensors; 2.5 Nuclear Receptors and Drug Transporters; 2.6 The ABC Superfamily; 2.6.1 ABCA Subfamily; 2.6.2 ABCB Subfamily; 2.6.3 ABCC Subfamily; 2.6.4 ABCD Subfamily; 2.6.5 ABCE and ABCF Subfamilies; 2.6.6 ABCG Subfamily; 2.7 SLC Superfamily; 2.7.1 Oligopeptide Transporters (SLC15A); 2.7.2 Folate Transporters (SLC19A)
- 2.7.3 Concentrative Nucleoside Transporters (SLC28A)2.7.4 Equilibrative Nucleoside Transporters (SLC29A); 2.7.5 Organic Anion Transporters (SLCO/SLC21); 2.7.6 Organic Cation Transporters (SLC22); 2.7.7 Multidrug and Toxin Extrusion Proteins (SLC47); 2.8 Conclusion; References; Chapter 3 Targeted Proteomics to Support Transporter IVIVE and PBPK; 3.1 Introduction; 3.1.1 In vitro to In vivo Extrapolation (IVIVE) of Transporter Activity; 3.2 Methods for Quantitative Proteomics; 3.2.1 Mass Spectrometry-based Proteomics
- 3.3 Utility of Transporter Proteomic Data in the Translation of Transporter Activity in Human Tissues3.3.1 IVIVE of Actively Transported Substrate Drugs; 3.3.2 IVIVE and PBPK of Hepatobiliary Transport; 3.3.3 IVIVE and PBPK of Intestinal Transport; 3.3.4 IVIVE and PBPK of Transport Through the Blood-Brain Barrier; 3.3.5 IVIVE and PBPK of Renal Transport; 3.4 Current Status and Future Challenges; References; Chapter 4 Interplay Between Enzymes and Transporters: Impact on the Prediction of Pharmacokinetics and Drug-Drug Interactions; 4.1 Introduction
- 4.2 Evidence of the Clinical Impact of the Interplay Between Enzymes and Transporters4.2.1 Impact of the Interplay Between Enzymes and Transporters on Absorption; 4.2.2 Impact of the Interplay Between Enzymes and Transporters on Distribution; 4.2.3 Impact of the Interplay Between Enzymes and Transporters on Elimination; 4.2.4 Interplay Due to Regulation of Enzymes and Transporters; 4.3 Prediction of the Impact of the Interplay Between Enzymes and Transporters on Pharmacokinetics; 4.3.1 Preclinical Investigation of the Enzyme-Transporter Interplay